- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06053268
Mindfulness Interventions to Improve Health Activation, Coping, and Stress Among Childhood Cancer Survivors
June 25, 2026 updated by: St. Jude Children's Research Hospital
This study will explore feasibility and acceptability of using a daily mobile mindfulness app to cope with stress. In addition, feasibility of digital health data collection procedures including wrist-worn devices and ecological momentary assessments will be examined.
PRIMARY OBJECTIVES
- Determine the feasibility and acceptability of completing the 30-day mobile mindfulness program
- Evaluate the feasibility of digital health data collection procedures to detect autonomic nervous system (ANS) activation associated with stress (e.g., electrodermal activity, pulse rate variability, skin temperature) via wearable devices and self-reported ecological momentary assessments (EMA) among adult survivors of childhood cancer in the SJLIFE cohort
- Generate preliminary data to estimate the effect size and power needed for an extramurally funded randomized controlled trials (RCT) examining the impact of daily mindfulness mediation on biomarkers of ANS activation, coping, health behaviors, and cardiometabolic outcomes in a cohort of survivors of childhood cancer.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Detailed Description
Prior to engaging in the intervention participants will complete baseline assessments of stress and coping.
Participants will then engage in a daily mindfulness practice via the Headspace mobile application.
The basic application program includes daily 10-minute sessions in guided mindfulness meditation that include mindful breathing, body awareness, emotion and thought recognition, and attentional control.
During the first and fourth week of the intervention, participants will complete EMAs assessing mood, current activity, and intervention engagement.
Participants will also wear a wrist-worn device to assess biomarkers of stress.
At the completion of the intervention participants will complete follow-up assessments related to intervention and data collection procedures feasibility and acceptability as well as coping behaviors and stress.
Study Type
Interventional
Enrollment (Actual)
50
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Tennessee
-
Memphis, Tennessee, United States, 38105
- St. Jude Children's Research Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Research participant is at least 18 years old at enrollment
- Research participant is followed by St. Jude Children's Research Hospital (SJCRH)
- Research participant has a diagnosis history of leukemia or lymphoma
- Research participant takes part in the St. Jude Lifetime Cohort Study (SJLIFE)
- Research participant has elevated psychological stress scores of 6 or greater on most recent SJLIFE questionnaire
- Participant can speak and read English
Exclusion Criteria:
- Research participant currently engages in mindful stress-reduction practices >2x per week (e.g., tai chi, meditation)
- Research participant takes psychiatric medications or medications that impact cardiac functioning, beta-blockers, alpha-blockers
- Research participant wears a pacemaker
- Research participant has a diagnosis of a congenital heart disease
- Research participant has no access to a smartphone
- Research participant has elevated pain interference scores (T≥70)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Single-arm, Within-subject Feasibility Pilot:
Single-arm, within-subject feasibility pilot: Participants completed a 30-day app-based mindfulness intervention with wearable biosensor monitoring, ecological momentary assessment, surveys, and blood specimen collection.
|
The intervention was delivered via the Headspace mobile application.
The basic application program includes daily 10-minute sessions in guided mindfulness meditation that include mindful breathing, body awareness, emotion and thought recognition, and attentional control
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Mindfulness App Adherence
Time Frame: 30 days (during intervention)
|
Mindfulness app adherence was defined as the proportion of participants who completed at least 4 meditation sessions on average during the 30-day intervention.
|
30 days (during intervention)
|
|
Intervention Acceptability
Time Frame: Up to 1 week post intervention
|
Treatment Acceptability and Adherence Scale - Participants will rate on a 0 ("Strongly disagree") to 7 ("Strongly agree") scale regarding their perceptions of acceptability of the mindfulness intervention (10 items).
Scores range from 0-70.
An overall score is provided with higher scores indicating higher intervention acceptability.
|
Up to 1 week post intervention
|
|
Ecological Momentary Assessment Data Collection Acceptability
Time Frame: Up to 1 week post intervention
|
An adapted version of the Treatment Acceptability and Adherence Scale was created to evaluate ecological momentary assessment acceptability (7 items).
Scores range from 0-49.
An overall score is provided with higher scores indicating higher intervention acceptability.
|
Up to 1 week post intervention
|
|
Biosensor (Wrist-worn Device) Adherence
Time Frame: Approximately 37 days over the study window (7-day baseline washout plus 30-day intervention)
|
Biosensor adherence was defined as the proportion of participants who wore the wrist-worn biosensor for at least 10 hours per day across the approximately 37-day study window.
|
Approximately 37 days over the study window (7-day baseline washout plus 30-day intervention)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Perceived Stress Scale
Time Frame: Baseline and up to 1 week post intervention
|
This measure is a 10-item, widely used and validated assessment of stress and efficacy of managing stress.
The Participants are asked to respond to each question on a 5-point Likert scale ranging from 0 (never) to 4 (very often), indicating how often they have felt or thought a certain way within the past month.
A single score is provided and ranges from 0 to 40.
Higher scores indicate higher levels of stress.
|
Baseline and up to 1 week post intervention
|
|
Brief Coping Orientation to Problems Experienced (COPE)
Time Frame: Baseline and up to 1 week post intervention
|
The Brief COPE is a validated measure of coping strategies.
Six subscales were included in this analysis: behavioral disengagement, planning, positive reframing, meditation/religious coping, self-blame, and emotional support.
Participants rated each item on a 4-point Likert scale, and subscale scores range from 2 to 8 for each domain, with higher scores indicating greater use of the given coping strategy.
Higher scores are not uniformly better or worse outcomes because interpretation depends on the coping strategy; for example, higher planning, positive reframing, and emotional support generally reflect greater use of adaptive coping strategies, whereas higher behavioral disengagement and self-blame reflect greater use of maladaptive coping strategies.
|
Baseline and up to 1 week post intervention
|
|
Oxidized Low-Density Lipoprotein
Time Frame: Baseline and up to 1 week post intervention
|
Oxidized low-density lipoprotein was measured from dried blood spot specimens as a biomarker of oxidative modification of low-density lipoprotein particles.
Values are reported in units per liter.
Higher values indicate greater oxidized low-density lipoprotein concentrations.
|
Baseline and up to 1 week post intervention
|
|
Pro-B-type Natriuretic Peptide
Time Frame: Baseline and up to 1 week post intervention
|
Pro-B-type natriuretic peptide was measured from dried blood spot specimens as a biomarker related to cardiac wall stress.
Values are reported as log-transformed concentrations in picograms per milliliter (log pg/mL).
Higher values indicate higher pro-B-type natriuretic peptide concentrations.
|
Baseline and up to 1 week post intervention
|
|
P-selectin
Time Frame: Baseline and up to 1 week post intervention
|
P-selectin was measured from dried blood spot specimens as a biomarker of platelet activation and vascular inflammation.
Values are reported as log-transformed concentrations in picograms per milliliter (log pg/mL).
Higher values indicate higher P-selectin concentrations.
|
Baseline and up to 1 week post intervention
|
|
Vascular Cell Adhesion Molecule-1
Time Frame: Baseline and up to 1 week post intervention
|
Vascular cell adhesion molecule-1 was measured from dried blood spot specimens as a biomarker of endothelial activation and vascular inflammation.
Values are reported in nanograms per milliliter.
Higher values indicate higher vascular cell adhesion molecule-1 concentrations.
|
Baseline and up to 1 week post intervention
|
|
Homocysteine
Time Frame: Baseline and up to 1 week post intervention
|
Homocysteine was measured from dried blood spot specimens as a biomarker related to vascular and cardiometabolic risk.
Values are reported in micromoles per liter.
Higher values indicate higher homocysteine concentrations.
|
Baseline and up to 1 week post intervention
|
|
High-sensitivity C-Reactive Protein
Time Frame: Baseline and up to 1 week post intervention
|
High-sensitivity C-reactive protein was measured from dried blood spot specimens as a biomarker of systemic inflammation.
Values are reported in milligrams per liter.
Higher values indicate higher systemic inflammation.
|
Baseline and up to 1 week post intervention
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Rachel Webster, PhD, St. Jude Children's Research Hospital
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 23, 2024
Primary Completion (Actual)
May 9, 2025
Study Completion (Estimated)
September 27, 2026
Study Registration Dates
First Submitted
September 7, 2023
First Submitted That Met QC Criteria
September 21, 2023
First Posted (Actual)
September 25, 2023
Study Record Updates
Last Update Posted (Actual)
July 23, 2026
Last Update Submitted That Met QC Criteria
June 25, 2026
Last Verified
June 1, 2026
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MINDHACS
- NCI-2023-09351 (Other Identifier: NCI Clinical Trial Registration Program)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
Individual participant de-identified datasets containing the variables analyzed in the published article will be made available (related to the study primary or secondary objectives contained in the publication).
Supporting documents such as the protocol, statistical analyses plan, and informed consent are available through the CTG website for the specific study.
Data used to generate the published article will be made available at the time of article publication.
Investigators who seek access to individual level de-identified data will contact the computing team in the Department of Biostatistics (ClinTrialDataRequest@stjude.org) who will respond to the data request.
IPD Sharing Time Frame
Data will be made available at the time of article publication.
IPD Sharing Access Criteria
Data will be provided to researchers following a formal request with the following information: full name of requestor, affiliation, data set requested, and timing of when data is needed.
As an informational point, the lead statistician and study principal investigator will be informed that primary results datasets have been requested.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.